29 results on '"K. Krischak"'
Search Results
2. Spontaneous Ureterocolic Fistula between Nonfunctioning Kidney Transplant Ureter and Colon in Setting of Diverticulitis
- Author
-
Madison K. Krischak, Jeffrey R. Ord, Ashton A. Connor, and Andrew S. Barbas
- Subjects
Surgery ,RD1-811 - Abstract
Ureterocolic fistula is a rare condition that most commonly occurs in the setting of diverticular disease. The development of a ureterocolic fistula following kidney transplantation is even rarer, with no prior cases in the literature to our knowledge. We describe the case of a patient with three prior failed kidney transplants who developed a fistula between the sigmoid colon and nonfunctioning renal transplant ureter in the setting of diverticulitis.
- Published
- 2021
- Full Text
- View/download PDF
3. Beyond Expert Opinion: A Comparison of Antibiotic Regimens for Infectious Urinary Tract Pathology in Pregnancy
- Author
-
Madison K. Krischak, Heather A. Rosett, Sarika Sachdeva, Kristin E. Weaver, Robert Phillips Heine, Anna E. Denoble, and Sarah K. Dotters-Katz
- Subjects
asymptomatic bacteriuria ,acute cystitis ,nitrofurantoin ,pyelonephritis ,trimethoprim-sulfamethoxazole ,uropathogen ,urinary tract infections ,Gynecology and obstetrics ,RG1-991 - Abstract
Objective Outside pregnancy, nitrofurantoin, ciprofloxacin and sulfamethoxazole-trimethoprim (SMZ-TMP) are first-line therapy (FLT) for lower urinary tract infections (LUTIs). Optimal antibiotics for LUTI have been extrapolated based on expert opinion. Progression to pyelonephritis and adverse obstetric outcomes were compared between women who received FLT and those given alternative antibiotics. Methods This study includes a retrospective cohort of women with LUTI, including asymptomatic bacteriuria and acute cystitis at single health care system from July 2013 to May 2019. Women receiving FLT, defined as nitrofurantoin or SMZ-TMP, were compared with those receiving nonfirst-line therapy (nFLT). Primary outcome was progression to pyelonephritis. Secondary outcomes included pyelonephritis-related anemia, sepsis, length of stay, preterm birth (PTB), and low birth weight (LBW). Logistic regression was used to calculate odds of outcomes. Results Of 476 women, 336 (70.6%) received FLT and 140 (29.4%) received nFLT. Women receiving FLT were more likely having BMI ≥ 40 (p = 0.04). Progression to pyelonephritis did not differ (5.8 vs. 8.2%; p = 0.44), nor did other pyelonephritis-related outcomes. After controlling for confounders, no difference in odds of progression to pyelonephritis was seen (adjusted odds ratio [aOR] 1.02, 95% confidence interval [CI] 0.42, 2.49). FLT was not associated with PTB or LBW (aOR 0.60, 95% CI 0.29, 1.26) after controlling for confounders. Conclusion Receipt of antibiotics other than nitrofurantoin or SMZ-TMP for LUTI in pregnancy was not associated with increased risk of progression to pyelonephritis, PTB, or LBW.
- Published
- 2020
- Full Text
- View/download PDF
4. Patient-Reported and Physiologic Outcomes Following Pelvic Exenteration for Non-Repairable Radiated Rectourethral Fistula
- Author
-
Madison K, Krischak, Joshua P, Hayden, Kevin, Krughoff, Brian M, Inouye, William R, Boysen, Christopher R, Mantyh, Detlev, Erdmann, and Andrew C, Peterson
- Subjects
Narcotics ,Pain, Postoperative ,Treatment Outcome ,Urinary Fistula ,Urology ,Urethral Diseases ,Quality of Life ,Humans ,Rectal Fistula ,Patient Reported Outcome Measures ,Pelvic Exenteration ,Retrospective Studies - Abstract
To investigate the impact of pelvic exenteration (PelvEX) on patient-reported pain, distress, and quality of life along with physiologic indicators of health in cancer survivors with radiated, non-repairable rectourethral fistula (RUF).We reviewed a prospectively maintained quality improvement database of RUF patients at our institution from 2012 to 2020. Patients with radiated, non-repairable RUF who underwent PelvEX and had follow up to 1 year were included. Pain and distress scores were collected preoperatively and at 1-year follow up. Number of narcotic prescriptions in the 3 months before surgery and the year after surgery were abstracted. Short Form 12 surveys were administered in the postoperative period. Serum albumin, creatinine, carbon dioxide, hematocrit, and glucose were abstracted from electronic health records. Statistical analysis was performed using Wilcoxon signed-rank and Mann-Whitney tests.Eleven patients met inclusion criteria. Patient-reported pain significantly decreased at 1 year follow-up compared to preoperative scores (median pre: 4 vs 1 year post: 0, P = .0312). Patient-reported distress significantly decreased pre- versus post-PelvEX (median pre: 5 vs post: 0, P = .0156). At the time of postoperative pain and distress surveys, 9 (82.8%) patients did not have narcotic prescriptions. Postoperative Short Form 12 scores were similar to an age-matched United States population (mental: P = .3125; physical: P = .1484). Serum-based indicators of health were not different in the pre- versus postoperative period (all P.05).PelvEX may be a valuable treatment option to decrease patient-reported pain and distress without compromising quality of life or physiologic health in patients with radiated, non-repairable RUF.
- Published
- 2022
- Full Text
- View/download PDF
5. The Importance of Early Diagnosis and Management of Pediatric Neurogenic Bladder Dysfunction
- Author
-
J. Todd Purves, John S. Wiener, Madison K. Krischak, Rohit Tejwani, K Tyler Hobbs, and Jonathan C. Routh
- Subjects
medicine.medical_specialty ,diagnosis ,Spina bifida ,business.industry ,Urology ,Urinary system ,neurogenic bladder ,Psychological intervention ,bladder dysfunction ,Urinary incontinence ,Review ,medicine.disease ,Early initiation ,spina bifida ,Regimen ,pediatric ,Pharmacotherapy ,medicine ,medicine.symptom ,Intensive care medicine ,business ,management ,Neurogenic bladder dysfunction - Abstract
Neurogenic bladder dysfunction is a major source of urologic morbidity in children, especially in those with spina bifida (SB). Complications from progression of bladder dysfunction can include urinary tract infections (UTIs), urinary incontinence, upper tract deterioration, and renal dysfunction or failure. In these children, there has been a recent trend toward proactive rather than expectant management of neurogenic bladder. However, there is a lack of consensus on how to best achieve the three main goals of neurogenic bladder management: 1) preserving kidney function, 2) achieving continence (if desired by the family/individual), and 3) achieving social and functional urologic independence (if appropriate). Hence, our objective was to perform a narrative literature review to evaluate the approaches to diagnosis and management of pediatric neurogenic bladder dysfunction, with special focus on children with SB. The approach strategies vary across a spectrum, with a proactive strategy on one end of the spectrum and an expectant strategy at the other end. The proactive management strategy is characterized by early and frequent labs, imaging, and urodynamic (UDS) evaluation, with early initiation of clean intermittent catheterization (CIC) and proceeding with pharmacotherapy, or surgery if indicated. The expectant management strategy prioritizes surveillance labs and imaging prior to proceeding with invasive assessments and interventions such as UDS or pharmacotherapy. Both treatment strategies are currently utilized and data have historically been inconclusive in demonstrating efficacy of one regimen over the other. We performed a narrative literature evaluating proactive and expectant treatment strategies as they relate to diagnostics and management of Spina Bifida. From the available literature and our practice, a proactive strategy favors greater benefit in preventative management and may decrease risk of renal dysfunction compared with expectant management.
- Published
- 2021
- Full Text
- View/download PDF
6. Adeno-associated virus mediates gene transduction after static cold storage treatment in rodent lung transplantation
- Author
-
Samuel J. Kesseli, Madison K. Krischak, Qimeng Gao, Trevor Gonzalez, Min Zhang, Samantha E. Halpern, Riley Kahan, Mingqing Song, Niki Huffman, Hongzhi Xu, Nader Abraham, Aravind Asokan, Andrew S. Barbas, and Matthew G. Hartwig
- Subjects
Pulmonary and Respiratory Medicine ,Surgery ,Cardiology and Cardiovascular Medicine - Published
- 2022
- Full Text
- View/download PDF
7. Same-teams versus different-teams for long distance lung procurement: A cost analysis
- Author
-
Danae G. Olaso, Samantha E. Halpern, Madison K. Krischak, Sandra Au, Ian R. Jamieson, John C. Haney, Jacob A. Klapper, and Matthew G. Hartwig
- Subjects
Pulmonary and Respiratory Medicine ,Surgery ,Cardiology and Cardiovascular Medicine - Abstract
In an era of broader lung sharing, different-team transplantation (DT, procuring team from nonrecipient center) may streamline procurement logistics; however, safety and cost implications of DT remain unclear. To understand whether DT represents a safe means to reduce lung transplant (LTx) costs, we compared posttransplant outcomes and lung procurement and index hospitalization costs among matched DT and same-team transplantation (ST, procuring team from recipient center) cohorts at a single, high-volume institution. We hypothesized that DT reduces costs without compromising outcomes after LTx.Patients who underwent DT between January 2016 to May 2020 were included. A cohort of patients who underwent ST was matched 1:3 (nearest neighbor) based on recipient age, disease group, lung allocation score, history of previous LTx, and bilateral versus single LTx. Posttransplant outcomes and costs were compared between groups.In total, 23 DT and 69 matched ST recipients were included. Perioperative outcomes and posttransplant survival were similar between groups. Compared with ST, DT was associated with similar lung procurement and index hospitalization costs (DT vs ST, procurement: median $65,991 vs $58,847, P = .16; index hospitalization: median $294,346 vs $322,189, P = .7). On average, procurement costs increased $3263 less per 100 nautical miles for DT versus ST; DT offered cost-savings when travel distances exceeded approximately 363 nautical miles.At our institution, DT and ST were associated with similar post-LTx outcomes; DT offered cost-savings with increasing procurement travel distance. These findings suggest that DT may mitigate logistical and financial burdens of lung procurement; however, further investigation in a multi-institutional cohort is warranted.
- Published
- 2023
- Full Text
- View/download PDF
8. Medical management of neurogenic bladder in patients with spina bifida: A scoping review
- Author
-
Rebecca J. Fairchild, Leonid I. Aksenov, Kevin T. Hobbs, Madison K. Krischak, Samantha J. Kaplan, J. Todd Purves, John S. Wiener, and Jonathan C. Routh
- Subjects
Urology ,Pediatrics, Perinatology and Child Health - Abstract
Neurogenic bladder is a common source of morbidity in patients with spina bifida and can cause renal damage. Medical management may include imaging, urodynamic studies (UDS), laboratory testing, clean intermittent catheterization (CIC), and medication. There is ongoing debate regarding the optimal management regimen. Approaches are described by two paradigms: proactive and expectant management. In a proactive approach, invasive interventions like CIC and UDS are initiated before the onset of renal abnormalities. In expectant management, UDS, CIC, and medications are started after abnormalities are identified. In this scoping review, we aim to comprehensively review existing literature on outcomes of proactive and expectant management of neurogenic bladder in patients with spina bifida.We searched multiple databases and screened articles for inclusion using PRISMA-ScR guidelines. Included studies reported clinical outcomes of any aspect of proactive or expectant neurogenic bladder management in patients with spina bifida.Ultimately, 74 articles were included for review including 67 cohort studies, 4 cross-sectional studies, 2 sequential cohort studies, and 1 randomized control trial. Eleven studies directly compared management strategies. There was substantial heterogeneity in study designs, management protocols, and reported outcomes. Most studies addressed multiple simultaneous aspects of management without specifically analyzing individual aspects. However, some commented on individual aspects of management including UDS (13), CIC (32), imaging (7), and medication (5). Although there was no consensus about optimal management, all direct comparisons of paradigms supported a proactive approach.Our review identified a broad body of literature about optimal management of neurogenic bladder. Existing studies vary greatly in terms of treatment protocols, measured outcomes, and management recommendations. Overall, studies that directly compare management are scarce but favor proactive management. Given the implications on clinical outcomes, it is crucial to focus future work on directly comparing management strategies and isolating the effects of different individual management elements.
- Published
- 2022
9. Beyond Expert Opinion: A Comparison of Antibiotic Regimens for Infectious Urinary Tract Pathology in Pregnancy
- Author
-
Sarika Sachdeva, Kristin Weaver, Heather Rosett, Sarah K. Dotters-Katz, Madison K. Krischak, R.P. Heine, and Anna E. Denoble
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Anemia ,Urinary system ,acute cystitis ,030106 microbiology ,nitrofurantoin ,lcsh:Gynecology and obstetrics ,trimethoprim-sulfamethoxazole ,03 medical and health sciences ,0302 clinical medicine ,uropathogen ,Internal medicine ,medicine ,030212 general & internal medicine ,lcsh:RG1-991 ,Pregnancy ,business.industry ,Obstetrics and Gynecology ,Retrospective cohort study ,Odds ratio ,asymptomatic bacteriuria ,medicine.disease ,female genital diseases and pregnancy complications ,Ciprofloxacin ,Low birth weight ,Nitrofurantoin ,Pediatrics, Perinatology and Child Health ,pyelonephritis ,Original Article ,urinary tract infections ,medicine.symptom ,business ,medicine.drug - Abstract
Objective Outside pregnancy, nitrofurantoin, ciprofloxacin and sulfamethoxazole-trimethoprim (SMZ-TMP) are first-line therapy (FLT) for lower urinary tract infections (LUTIs). Optimal antibiotics for LUTI have been extrapolated based on expert opinion. Progression to pyelonephritis and adverse obstetric outcomes were compared between women who received FLT and those given alternative antibiotics. Methods This study includes a retrospective cohort of women with LUTI, including asymptomatic bacteriuria and acute cystitis at single health care system from July 2013 to May 2019. Women receiving FLT, defined as nitrofurantoin or SMZ-TMP, were compared with those receiving nonfirst-line therapy (nFLT). Primary outcome was progression to pyelonephritis. Secondary outcomes included pyelonephritis-related anemia, sepsis, length of stay, preterm birth (PTB), and low birth weight (LBW). Logistic regression was used to calculate odds of outcomes. Results Of 476 women, 336 (70.6%) received FLT and 140 (29.4%) received nFLT. Women receiving FLT were more likely having BMI ≥ 40 (p = 0.04). Progression to pyelonephritis did not differ (5.8 vs. 8.2%; p = 0.44), nor did other pyelonephritis-related outcomes. After controlling for confounders, no difference in odds of progression to pyelonephritis was seen (adjusted odds ratio [aOR] 1.02, 95% confidence interval [CI] 0.42, 2.49). FLT was not associated with PTB or LBW (aOR 0.60, 95% CI 0.29, 1.26) after controlling for confounders. Conclusion Receipt of antibiotics other than nitrofurantoin or SMZ-TMP for LUTI in pregnancy was not associated with increased risk of progression to pyelonephritis, PTB, or LBW.
- Published
- 2020
- Full Text
- View/download PDF
10. The Systemic Immune-Inflammation Index Predicts Clinical Outcomes in Kidney Transplant Recipients
- Author
-
Dimitrios Moris, Brian I. Shaw, Samantha E. Halpern, Samuel J. Kesseli, Andrew S. Barbas, Kadiyala V. Ravindra, Danae G. Olaso, Lisa M. McElroy, and Madison K. Krischak
- Subjects
Adult ,Oncology ,Cancer Research ,medicine.medical_specialty ,Neutrophils ,Lymphocyte ,General Biochemistry, Genetics and Molecular Biology ,Internal medicine ,medicine ,Humans ,Lymphocyte Count ,Kidney transplantation ,Retrospective Studies ,Inflammation ,Pharmacology ,business.industry ,Proportional hazards model ,Area under the curve ,Prognosis ,medicine.disease ,Kidney Transplantation ,Delayed Graft Function ,Transplantation ,medicine.anatomical_structure ,Absolute neutrophil count ,business ,Research Article ,Immune inflammation - Abstract
Background Outcomes after kidney transplantation (KTx) remain limited by delayed graft function (DGF) and acute rejection. Non-invasive biomarkers may help identify patients at increased risk for these events. We examined the association between the systemic immune-inflammation index (SII), a novel inflammatory biomarker, and outcomes after KTx and evaluated its ability to predict post-transplant prognosis. Patients and methods Adult patients who underwent primary KTx at our institution between 2016-2019 were included. SII was calculated from pre-transplant complete blood counts as the ratio of the neutrophil count to the lymphocyte count multiplied by the platelet count. The cutoff between high and low SII was determined by maximizing the area under the curve. Multivariable logistic and Cox regression were used to identify factors associated with DGF and patient, rejection-free, and graft survival respectively. Results Overall, 378 KTx recipients were included; 224 (59.3%) had high SII. On unadjusted analysis, high SII was associated with reduced odds of DGF, and improved patient and rejection-free survival. After adjustment, high SII was independently associated with improved patient survival alone. Multivariable models incorporating SII performed well for the prediction of DGF (c-statistic=0.755) and patient survival (c-statistic=0.786), though rejection-free survival was more difficult to predict (c-statistic=0.635). Conclusion SII demonstrated limited utility as an independent predictor of outcomes after KTx. However, in combination with other clinically relevant parameters, SII is a useful predictor of post-KTx prognosis. Validation of this novel inflammatory biomarker in a multi-institutional study is needed to further elucidate its practical applications in transplantation.
- Published
- 2020
- Full Text
- View/download PDF
11. Resection of Pubic Symphysis and Cystectomy Significantly Improves Short-Term Patient-Reported Physical Functioning Among Patients With Pubovesical Fistula and Pubic Bone Osteomyelitis
- Author
-
Brian M. Inouye, Madison K. Krischak, Kevin Krughoff, William R. Boysen, and Andrew C. Peterson
- Subjects
Male ,Narcotics ,Morphine Derivatives ,Fistula ,Urology ,Prostatic Neoplasms ,Pubic Symphysis ,Osteomyelitis ,Cystectomy ,Quality of Life ,Humans ,Patient Reported Outcome Measures ,Aged ,Pubic Bone - Abstract
To investigate the impact of extirpative surgery for pubic bone osteomyelitis with pubovesical fistula on prostate cancer survivors' physical and mental health.The Short Form 12 (SF-12) is a validated instrument for assessing health-related quality of life (HRQOL). We reviewed a prospectively maintained database of patients treated with extirpative surgery for pubovesical fistula from 2017-2021 who completed the SF-12. Wilcoxon signed-rank and McNemar's tests were used to analyze changes in SF-12 following surgery. Narcotic prescriptions in the year before and after surgery were assessed as an additional measure of pain burden.Eighteen patients were included. Four had pre-operative SF-12s, 3 had post-operative SF-12s, and 11 had both. Median age was 76.5 years (IQR 71.75-80.00). All patients had previous radiation for prostate cancer. Compared to global pre-operative scores, post-operative physical composite scores (PCS) significantly increased (29.95 ± 8.59 vs 42.48 ± 7.18; P.001), but mental composite scores (MCS) were similar (45.35 ± 9.98 vs 52.21 ± 8.23). When comparing individual, paired pre-operative and post-operative scores there was a significant improvement in PCS (30.56 ± 9.87 vs 45.45 ± 8.56; P = .005), but not MCS (47.49 ± 6.92 vs 51.60 ± 8.88). Median morphine milligram equivalent significantly decreased in the year post-surgery compared to the year prior (103.1, 33.0-250.9 vs 34.25, 0.0-105.9; P = .0008).For prostate cancer survivors with pubovesical fistula and pubic bone osteomyelitis, urinary diversion with pubic bone resection improves physical functioning and decreases narcotic prescriptions without untoward effects on mental health.
- Published
- 2022
12. Textbook surgical outcome in lung transplantation: Analysis of a US national registry
- Author
-
Madison K. Krischak, Sandra Au, Samantha E. Halpern, Danae G. Olaso, Dimitrios Moris, Laurie D. Snyder, Andrew S. Barbas, John C. Haney, Jacob A. Klapper, and Matthew G. Hartwig
- Subjects
Adult ,Transplantation ,Treatment Outcome ,Graft Survival ,Humans ,Registries ,Tissue Donors ,Lung Transplantation ,Retrospective Studies - Abstract
Textbook surgical outcome (TO) is a novel composite quality measure in lung transplantation (LTx). Compared to 1-year survival metrics, TO may better differentiate center performance, and motivate improvements in care. To understand the feasibility of implementing this metric, we defined TO in LTx using US national data, and evaluated its ability to predict post-transplant outcomes and differentiate center performance.Adult patients who underwent isolated LTx between 2016 and 2019 were included. TO was defined as freedom from post-transplant length of stay 30 days, 90-day mortality, intubation or extracorporeal membrane oxygenation at 72 h post-transplant, post-transplant ventilator support lasting ≥5 days, postoperative airway dehiscence, inpatient dialysis, pre-discharge acute rejection, and grade 3 primary graft dysfunction at 72 h. Recipient and donor characteristics and post-transplant outcomes were compared between patients who achieved and failed TO.Of 8959 lung transplant recipients, 4664 (52.1%) achieved TO. Patient and graft survival were improved among patients who achieved TO (both log-rank P .0001). Among 62 centers, adjusted rates of TO ranged from 27.0% to 72.4% reflecting a wide variability in center-level performance.TO defined using national data may represent a novel composite metric to guide quality improvement in LTx across US transplant centers.In this study we defined textbook outcome (TO) for lung transplantation (LTx) using US national data. We found that achievement of TO was associated with improved post-transplant survival, and wide variability in center-level LTx performance. These findings suggest that TO could be readily implemented to compare quality of care among US LTx centers.
- Published
- 2021
13. Lung transplantation after ex-vivo lung perfusion versus static cold storage: An institutional cost analysis
- Author
-
John C. Haney, Samantha E. Halpern, Jacob A. Klapper, Greg Tipton, Samuel J. Kesseli, Danae G. Olaso, Ian R. Jamieson, Andrew S. Barbas, Sandra Au, Haley Smith, Madison K. Krischak, and Matthew G. Hartwig
- Subjects
Transplantation ,Lung ,business.industry ,medicine.medical_treatment ,Ex vivo lung perfusion ,Cold storage ,Organ Preservation ,Institutional level ,Article ,Tissue Donors ,Perfusion ,medicine.anatomical_structure ,Anesthesia ,medicine ,Lung preservation ,Cost analysis ,Costs and Cost Analysis ,Immunology and Allergy ,Lung transplantation ,Humans ,Pharmacology (medical) ,business ,Index hospitalization ,Lung Transplantation - Abstract
Ex vivo lung perfusion (EVLP) is a novel lung preservation strategy that facilitates the use of marginal allografts; however, it is more expensive than static cold storage (SCS). To understand how preservation method might affect postoperative costs, we compared outcomes and index hospitalization costs among matched EVLP and SCS preserved lung transplant (LTx) recipients at a single, high-volume institution. A total of 22 EVLP and 66 matched SCS LTx recipients were included; SCS grafts were further stratified as either standard-criteria (SCD) or extended-criteria donors (ECD). Median total preservation time was 857, 409, and 438 min for EVLP, SCD, and ECD lungs, respectively (p .0001). EVLP patients had similar perioperative outcomes and posttransplant survival compared to SCS SCD and ECD recipients. Excluding device-specific costs, total direct variable costs were similar among EVLP, SCD, and ECD recipients (median $200,404, vs. $154,709 vs. $168,334, p = .11). The median direct contribution margin was positive for EVLP recipients, and similar to that for SCD and ECD graft recipients (all p .99). These findings demonstrate that the use of EVLP was profitable at an institutional level; however, further investigation is needed to better understand the financial implications of EVLP in facilitating donor pool expansion in an era of broader lung sharing.
- Published
- 2021
14. Spontaneous Ureterocolic Fistula between Nonfunctioning Kidney Transplant Ureter and Colon in Setting of Diverticulitis
- Author
-
Jeffrey R. Ord, Andrew S. Barbas, Madison K. Krischak, and Ashton A. Connor
- Subjects
Kidney ,medicine.medical_specialty ,RD1-811 ,business.industry ,Fistula ,Sigmoid colon ,Case Report ,Diverticulitis ,medicine.disease ,Kidney transplant ,digestive system diseases ,Surgery ,03 medical and health sciences ,0302 clinical medicine ,medicine.anatomical_structure ,Ureter ,surgical procedures, operative ,030220 oncology & carcinogenesis ,Management of Technology and Innovation ,Diverticular disease ,Medicine ,030211 gastroenterology & hepatology ,business ,Kidney transplantation - Abstract
Ureterocolic fistula is a rare condition that most commonly occurs in the setting of diverticular disease. The development of a ureterocolic fistula following kidney transplantation is even rarer, with no prior cases in the literature to our knowledge. We describe the case of a patient with three prior failed kidney transplants who developed a fistula between the sigmoid colon and nonfunctioning renal transplant ureter in the setting of diverticulitis.
- Published
- 2021
15. Lung transplantation using allografts with more than 8 hours of ischemic time: A single-institution experience
- Author
-
Brandi A. Bottiger, Danae G. Olaso, Sandra Au, Madison K. Krischak, Samuel J. Kesseli, John C. Haney, Jacob A. Klapper, Matthew G. Hartwig, and Samantha E. Halpern
- Subjects
Pulmonary and Respiratory Medicine ,Adult ,Lung Diseases ,Male ,medicine.medical_specialty ,Time Factors ,medicine.medical_treatment ,Primary Graft Dysfunction ,030230 surgery ,Article ,03 medical and health sciences ,0302 clinical medicine ,Extracorporeal Membrane Oxygenation ,Extracorporeal membrane oxygenation ,medicine ,North Carolina ,Lung transplantation ,Humans ,Aged ,Retrospective Studies ,Mechanical ventilation ,Transplantation ,Lung ,business.industry ,Graft Survival ,Perioperative ,Middle Aged ,Allografts ,Tissue Donors ,Surgery ,Survival Rate ,surgical procedures, operative ,medicine.anatomical_structure ,030228 respiratory system ,Cohort ,Female ,Cardiology and Cardiovascular Medicine ,business ,Perfusion ,Follow-Up Studies ,Lung Transplantation - Abstract
BACKGROUND: Six hours was historically regarded as the limit of acceptable ischemic time for lung allografts. However, broader sharing of donor lungs often necessitates use of allografts with ischemic time >6 hours. We characterized the association between ischemic time ≥8 hours and outcomes after lung transplantation using a contemporary cohort from a high-volume institution. METHODS: Patients who underwent primary isolated bilateral lung transplantation between 1/2016–5/2020 were included. Patients bridged to transplant with extracorporeal membrane oxygenation or mechanical ventilation, and ex-vivo perfusion cases were excluded. Recipients were stratified by total allograft ischemic time
- Published
- 2021
16. Bad bugs: antibiotic-resistant bacteriuria in pregnancy and risk of pyelonephritis
- Author
-
R. Phillips Heine, Sarah K. Dotters-Katz, Annalies Denoble, Hadley W. Reid, Kristin Weaver, Heather Rosett, Sarika Sachdeva, and Madison K. Krischak
- Subjects
Male ,medicine.medical_specialty ,Bacteriuria ,medicine.drug_class ,Urinary system ,Antibiotics ,Article ,Sepsis ,Antibiotic resistance ,Pregnancy ,Internal medicine ,medicine ,Humans ,Acute Cystitis ,Pregnancy Complications, Infectious ,Retrospective Studies ,Pyelonephritis ,business.industry ,Infant, Newborn ,Retrospective cohort study ,General Medicine ,medicine.disease ,Anti-Bacterial Agents ,Urinary Tract Infections ,Premature Birth ,Female ,business - Abstract
The introduction of antibiotics has significantly reduced morbidity and mortality from microbial infections, but the rise of antibiotic-resistant and multidrug-resistant microbes is of increasing clinical concern. Few studies have examined the prevalence and impact of antibiotic resistance in common antenatal infections.This study aimed to determine whether pregnant women with a urine culture positive for antibiotic-resistant or multidrug-resistant gram-negative bacteria are at increased risk of developing pyelonephritis than pregnant women infected with antibiotic-susceptible organisms.This was a retrospective cohort study of pregnant women with asymptomatic bacteriuria or acute cystitis from a single health system from July 2013 to May 2019. Women with gram-negative antibiotic-resistant (resistance to 1-2 antibiotic classes) and multidrug-resistant (resistance to ≥3 antibiotic classes) lower urinary tract infections were compared with women with antibiotic-susceptible urinary tract infections in terms of demographic, infectious, antepartum, and intrapartum data. The primary outcome was pyelonephritis, defined as a billing code for pyelonephritis plus fever or flank pain. The secondary outcomes were length of stay in the hospital because of pyelonephritis, a composite of pyelonephritis complications (renal abscess, sepsis, and intensive care unit admission), and preterm delivery. The differences in the primary outcome were analyzed using multivariate logistic regression.A total of 573 women were eligible for inclusion. Of the 573 women, 334 (58%) had gram-negative bacteria on urine culture. Of the 334 cases, 173 (52%) were antibiotic susceptible, 74 (22%) were antibiotic resistant, and 87 (26%) were multidrug resistant. Women with antibiotic-resistant and multidrug-resistant infections were more likely to have hypertension (P=.004), to be Black (P=.03), to have public insurance (P=.002), and to experience more urinary infections (P=.001). Pyelonephritis was more common in women with antibiotic-resistant (adjusted odds ratio, 2.27; 95% confidence interval, 1.08-4.78) and multidrug-resistant (adjusted odds ratio, 3.06; 95% confidence interval, 1.57-5.96) infections than in women with antibiotic-susceptible urinary tract infections. Length of stay, preterm delivery, and pyelonephritis complications did not differ between antibiotic-susceptible and antibiotic-resistant and multidrug-resistant infections.In an age of increasing antibiotic resistance, more than one-half of pregnant women with bacteriuria experience at least 1 infection with an antibiotic-resistant organism. These resistance patterns have a real clinical impact as pregnant women with antibiotic-resistant gram-negative lower urinary tract infections have an estimated 2- to 3-fold increased odds of developing pyelonephritis.
- Published
- 2022
- Full Text
- View/download PDF
17. Lower Urinary Pathogens: Do More Pathogenic Bacteria Increase the Risk of Pyelonephritis?
- Author
-
Sarah K. Dotters-Katz, R.P. Heine, Anna E. Denoble, Heather Rosett, Sarika Sachdeva, Kristin Weaver, and Madison K. Krischak
- Subjects
Male ,medicine.medical_specialty ,Klebsiella ,Urinary system ,medicine.disease_cause ,Preeclampsia ,03 medical and health sciences ,0302 clinical medicine ,Pre-Eclampsia ,Pregnancy ,Internal medicine ,medicine ,Escherichia coli ,Humans ,030212 general & internal medicine ,Pregnancy Complications, Infectious ,Retrospective Studies ,030219 obstetrics & reproductive medicine ,biology ,Bacteria ,Pyelonephritis ,business.industry ,Infant, Newborn ,Obstetrics and Gynecology ,Pathogenic bacteria ,Enterobacter ,Odds ratio ,medicine.disease ,biology.organism_classification ,Anti-Bacterial Agents ,Proteus ,Pediatrics, Perinatology and Child Health ,Urinary Tract Infections ,Premature Birth ,Female ,business - Abstract
Objective Outside of pregnancy, urinary pathogens such as Proteus and Klebsiella are considered more pathogenic than E. coli. During pregnancy, the implications of lower urinary tract infection (LUTI) with more pathogenic bacteria are unclear. Thus, we sought to compare the risk of progression from LUTI to pyelonephritis among women infected with these more pathogenic urinary bacteria to those infected with E. coli. Study Design Retrospective cohort of pregnant women with LUTI at single tertiary center from July 2013 to May 2019. Pathogenic infections (PI) were defined as asymptomatic bacteriuria or acute cystitis urinary cultures positive for Proteus, Klebsiella, Enterobacter, Citrobacter, Acinetobacter, Staphylococcus, or Raoultella species. Demographic, infectious, antepartum, and postpartum data abstracted. Pregnant women with PI compared with those with E. coli. Primary outcome was progression to pyelonephritis. Secondary outcomes included pyelonephritis length of stay (LOS) >6 days, preterm birth (PTB), low birthweight (LBW), and measures of pyelonephritis-related morbidity. Results Of 686 pregnant women with LUTIs, 313 had urine culture growing out either PI or E. coli, with 59 (12%) growing PI and 254 (54%) growing E. coli. Women with PI were more likely to be African American, have chronic hypertension, and have history of preeclampsia. The primary species causing PI were Klebsiella (n = 29) and Proteus (n = 11). PI were not more likely to progress to pyelonephritis than E. coli LUTIs (10.9 vs. 14.5%; p = 0.67). Median LOS for pyelonephritis and other measures of pyelonephritis-related morbidity did not differ nor did PTB or LBW rates. After controlling for race, body mass index, history of preeclampsia, and history of pyelonephritis, PI were not associated with increased odds of progression to pyelonephritis (adjusted odds ratio: 0.69, 95% confidence interval: 0.27–1.80). Conclusion Bacteria traditionally considered to be more pathogenic outside of pregnancy do not progress to pyelonephritis at higher rates than E. coli in pregnancy, and are associated with similar pyelonephritis-related morbidity. Larger studies are needed to confirm these findings. Key Points
- Published
- 2020
18. Lung transplantation during the COVID-19 pandemic: Safely navigating the new 'normal'
- Author
-
Madison K. Krischak, Matthew G. Hartwig, Samantha E. Halpern, Jacob A. Klapper, Danae G. Olaso, John C. Haney, and John Reynolds
- Subjects
Male ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,medicine.medical_treatment ,Comorbidity ,030230 surgery ,03 medical and health sciences ,0302 clinical medicine ,Pandemic ,Immunology and Allergy ,Medicine ,Lung transplantation ,Humans ,Pharmacology (medical) ,Pandemics ,Aged ,Retrospective Studies ,Transplantation ,business.industry ,SARS-CoV-2 ,COVID-19 ,Middle Aged ,Tissue Donors ,Transplant Recipients ,United States ,Donor lungs ,New normal ,Emergency medicine ,Female ,business ,Lung Transplantation - Abstract
In the United States, an overall national decline in organ transplants has accompanied the substantial burden of COVID-19. Amidst significant regional variations in COVID-19, lung transplantation (LTx) remains a critical life-saving operation. Our LTx practice during the early pandemic may provide a blueprint for managing LTx in an era of continued community prevalence. Patients who underwent LTx at our institution between March 1 and May 20, 2020 were included. Recipient, operative, and donor characteristics were compared to those from our program in 2019, and COVID-19 testing practices were evaluated for March, April, and May to understand how our practice adapted to the pandemic. Our program performed 36 LTx, 33% more than the same period in 2019. Recipient, operative, and donor characteristics during COVID-19 were similar to those in 2019. By April 1, all donors and recipients underwent pretransplant COVID-19 testing, all returning negative results. To date, no recipients have developed posttransplant COVID-19. At our institution, pretransplant COVID-19 testing, use of local donor lungs, and avoidance of donors from areas of increased community penetration supported a safe and effective LTx practice during the early COVID-19 pandemic. Continued follow-up is required to ensure the long-term safety of these newly transplanted patients.
- Published
- 2020
19. Duct of Luschka Bile Leak Following Deceased Donor Liver Transplant
- Author
-
Madison K. Krischak, Jeffrey R. Ord, Andrew S. Barbas, and Jigesh A. Shah
- Subjects
Adult ,medicine.medical_specialty ,Leak ,Cirrhosis ,medicine.medical_treatment ,Bile Duct Diseases ,Liver transplantation ,Primary sclerosing cholangitis ,medicine ,Living Donors ,Bile ,Humans ,Accessory bile duct ,Intraoperative Complications ,Deceased donor ,business.industry ,General Medicine ,Perioperative ,Articles ,medicine.disease ,Surgery ,Liver Transplantation ,Female ,Bile Ducts ,business - Abstract
Patient: Female, 41-year-old Final Diagnosis: Primary sclerosing cholangitis Symptoms: Abdominal pain Medication:— Clinical Procedure: — Specialty: Transplantology Objective: Unusual or unexpected effect of treatment Background: Biliary leak is a relatively uncommon but potentially severe complication of liver transplantation. Duct of Luschka (also known as subvesical bile ducts) is a term that refers to a number of accessory biliary ducts. While leaks from Ducts of Luschka are well-described in the field of hepatobiliary surgery, only 2 case reports of such leaks exist in the setting of liver transplant. Case Report: We report the first case of a Duct of Luschka biliary leak seen after DCD liver transplant in a 41-year-old woman with cirrhosis secondary to primary sclerosing cholangitis. The patient underwent surgical re-exploration in the immediate postoperative period due to bilious output from a surgical drain. A Duct of Luschka was found intraoperatively at the gallbladder fossa and was oversewn. Apart from immunosuppression-related neutropenia, the patient recovered uneventfully. Conclusions: Given the variability in preoperative detection of subvesical bile ducts, accessory bile duct leak remains an important consideration in the liver transplant perioperative period. The prevalence of Ducts of Luschka and the relative risk of leakage from such subvesical bile ducts in liver transplants compared to cholecystectomies are unclear. Further research into anatomical accessory bile duct variants and preoperative techniques for detecting such ducts is warranted.
- Published
- 2021
20. 490: GBS Urinary Tract Infections: Is the risk of pyelonephritis as high as with E. Coli?
- Author
-
Anna E. Denoble, Kristin Weaver, Sarika Sachdeva, Heather Rosett, Madison K. Krischak, Phillips Heine, and Sarah K. Dotters-Katz
- Subjects
business.industry ,Urinary system ,Obstetrics and Gynecology ,Medicine ,business ,Microbiology - Published
- 2020
- Full Text
- View/download PDF
21. Strategic research agenda for biomedical imaging
- Author
-
C. Matos, W. Niessen, Karen Rosendahl, M. Gunther, Yun Liu, Philippe L. Pereira, C. Garos, U. Mayerhofer-Sebera, Christoph Hoeschen, Xavier Golay, Marc Dewey, A. Frangi, M. G. Myriam Hunink, Michal Neeman, H. Barthel, Steven Sourbron, Antonio Pifferi, V. Valentini, Gabriel P. Krestin, V. Dousset, Hans-Ulrich Kauczor, P. Gordebeke, M. Crean, A. Alberich, Konstantin Nikolaou, Andrea Rockall, Oliver Speck, A. Almen, H. Hahn, Luis Martí-Bonmatí, Owen J. Arthurs, F. Demuth, Katrine Riklund, Georg Langs, Silvio Aime, N. de Souza, K. Krischak, Olivier Clément, Francesco Sardanelli, Anders Persson, M. Hierath, P. Zolda, Jonathan P. McNulty, K. Muylle, and Imperial College Healthcare NHS Trust- BRC Funding
- Subjects
lcsh:Medical physics. Medical radiology. Nuclear medicine ,Medicin och hälsovetenskap ,Artificial intelligence ,Knowledge management ,European Institute for Biomedical Imaging Research (EIBIR) ,lcsh:R895-920 ,Medical and Health Sciences ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Health care ,Medical imaging ,Strategic research ,Medicine ,Radiology, Nuclear Medicine and imaging ,Preventive medicine ,Science & Technology ,business.industry ,Radiology, Nuclear Medicine & Medical Imaging ,Precision medicine ,030220 oncology & carcinogenesis ,Diagnostic imaging ,Radiology ,Statement ,business ,Life Sciences & Biomedicine ,Derived Data - Abstract
This Strategic Research Agenda identifies current challenges and needs in healthcare, illustrates how biomedical imaging and derived data can help to address these, and aims to stimulate dedicated research funding efforts.Medicine is currently moving towards a more tailored, patient-centric approach by providing personalised solutions for the individual patient. Innovation in biomedical imaging plays a key role in this process as it addresses the current needs for individualised prevention, treatment, therapy response monitoring, and image-guided surgery.The use of non-invasive biomarkers facilitates better therapy prediction and monitoring, leading to improved patient outcomes. Innovative diagnostic imaging technologies provide information about disease characteristics which, coupled with biological, genetic and -omics data, will contribute to an individualised diagnosis and therapy approach.In the emerging field of theranostics, imaging tools together with therapeutic agents enable the selection of best treatments and allow tailored therapeutic interventions.For prenatal monitoring, the use of innovative imaging technologies can ensure an early detection of malfunctions or disease.The application of biomedical imaging for diagnosis and management of lifestyle-induced diseases will help to avoid disease development through lifestyle changes.Artificial intelligence and machine learning in imaging will facilitate the improvement of image interpretation and lead to better disease prediction and therapy planning.As biomedical imaging technologies and analysis of existing imaging data provide solutions to current challenges and needs in healthcare, appropriate funding for dedicated research is needed to implement the innovative approaches for the wellbeing of citizens and patients. ispartof: INSIGHTS INTO IMAGING vol:10 issue:1 ispartof: location:Germany status: published
- Published
- 2019
22. Lung Transplantation Using Allografts with Extreme Ischemic Time: A Single-Institution Experience
- Author
-
Brandi A. Bottiger, Danae G. Olaso, Madison K. Krischak, Samantha E. Halpern, Jacob A. Klapper, Sandra Au, John C. Haney, Samuel J. Kesseli, and M.G. Hartwig
- Subjects
Pulmonary and Respiratory Medicine ,Mechanical ventilation ,Transplantation ,medicine.medical_specialty ,Lung ,business.industry ,medicine.medical_treatment ,Ischemic time ,Perioperative ,Surgery ,medicine.anatomical_structure ,Cohort ,medicine ,Lung transplantation ,Single institution ,Cardiology and Cardiovascular Medicine ,business ,Perfusion - Abstract
Purpose Six hours has historically been regarded as the limit of acceptable ischemic time (IT) for lung allografts. However, smarter sharing of donor lungs often necessitates use of allografts with IT >6 hours. We characterized the association between IT ≥8 hours and outcomes after lung transplantation (LTx) using a contemporary cohort from a high-volume institution. We hypothesized that longer ITs do not predict greater mortality or graft failure. Methods Patients who underwent primary isolated bilateral orthotopic LTx between 1/2016-5/2020 were included. Patients bridged to LTx with ECMO or mechanical ventilation, and ex-vivo perfusion cases were excluded. Recipients were stratified by allograft IT Results Of 358 patients, 95 (26.5%) received IT ≥8h lungs. IT ≥8h recipients were more likely to be male (69.5% vs 54.4%, p=0.01) and have DCD donors (20.0% vs 5.3%, p Conclusion In a modern cohort, use of lung allografts with IT ≥8h was associated with similar perioperative outcomes and post-transplant survival. Further investigation is required to better understand how broader use impacts post-LTx outcomes and the implications for smarter sharing under an evolving national allocation policy.
- Published
- 2021
- Full Text
- View/download PDF
23. 470: Lower urinary pathogens: Do more virulent bacteria increase the risk of pyelonephritis?
- Author
-
Kristin Weaver, Sarah K. Dotters-Katz, Heather Rosett, Anna E. Denoble, Phillips Heine, Sarika Sachdeva, and Madison K. Krischak
- Subjects
business.industry ,Urinary system ,Obstetrics and Gynecology ,Medicine ,Virulence ,business ,Microbiology - Published
- 2020
- Full Text
- View/download PDF
24. 268: Beyond expert opinion: A comparison of antibiotic regimens for infectious urinary tract pathology in pregnancy
- Author
-
Sarah K. Dotters-Katz, Phillips Heine, Anna E. Denoble, Heather Rosett, Kristin Weaver, Madison K. Krischak, and Sarika Sachdeva
- Subjects
medicine.medical_specialty ,Pregnancy ,business.industry ,medicine.drug_class ,Expert opinion ,Urinary system ,Antibiotics ,medicine ,Obstetrics and Gynecology ,Intensive care medicine ,medicine.disease ,business - Published
- 2020
- Full Text
- View/download PDF
25. 1069: Bad bugs: antibiotic-resistant lower urinary tract infections and risk of pyelonephritis in pregnancy
- Author
-
Phillips Heine, Kristin Weaver, Heather Rosett, Madison K. Krischak, Sarah K. Dotters-Katz, Anna E. Denoble, and Sarika Sachdeva
- Subjects
medicine.medical_specialty ,Pregnancy ,Antibiotic resistance ,business.industry ,Urinary system ,Internal medicine ,medicine ,Obstetrics and Gynecology ,medicine.disease ,business - Published
- 2020
- Full Text
- View/download PDF
26. Proteomic and Phosphoproteomic Analysis Reveals that Neurokinin-1 Receptor (NK1R) Blockade with Aprepitant in Human Keratinocytes Activates a Distinct Subdomain of EGFR Signaling: Implications for the Anti-Pruritic Activity of NK1R Antagonists
- Author
-
Madan M. Kwatra, Callie Roberts, Amy H. Huang, Raveena Khanna, Yevgeniy R. Semenov, Emily Boozalis, Cory Nanni, Madison K. Krischak, Shawn G. Kwatra, Robert F. Burns, and Kyle A. Williams
- Subjects
erlotinib ,EGFR ,Article ,03 medical and health sciences ,0302 clinical medicine ,Tachykinin receptor 1 ,medicine ,Epidermal growth factor receptor ,Receptor ,Aprepitant ,030304 developmental biology ,General Environmental Science ,aprepitant ,0303 health sciences ,biology ,Chemistry ,Cell growth ,General Engineering ,pruritus ,3. Good health ,NK1R ,HaCaT ,neurokinin1-receptor ,030220 oncology & carcinogenesis ,Cancer research ,biology.protein ,General Earth and Planetary Sciences ,Phosphorylation ,Erlotinib ,epidermal growth factor receptor ,medicine.drug - Abstract
Background: Epidermal growth factor receptor (EGFR) inhibitors can cause serious cutaneous toxicities, including pruritus and papulopustular acneiform skin eruptions. Increasingly, the neurokinin-1 receptor (NK1R) antagonist aprepitant is being utilized as an anti-pruritic agent in the treatment of EGFR-inhibitor induced pruritus. Aprepitant is believed to reduce itching by blocking NK1R on the surface of dermal mast cells. However, the effects of aprepitant on human keratinocytes remains unexplored. Methods: Herein, we examine the effects of aprepitant on EGFR stimulation in HaCaT cells using a phosphoproteomic approach including reverse phase protein arrays and Ingenuity Pathway Analysis. Changes in EGFR phosphorylation were visualized using Western blotting and the effect of EGF and aprepitant on the growth of HaCaT cells was determined using the WST-1 Cell Proliferation Assay System. Results: We found that aprepitant increased the phosphorylation of EGFR, as well as 10 of the 23 intracellular proteins phosphorylated by EGF. Analysis of phosphoproteomic data using Ingenuity Pathway Analysis software revealed that 5 of the top 10 pathways activated by EGF and aprepitant are shared. Conclusions: We propose that aprepitant produces its antipruritic effects by partially activating EGFR. Activation of EGFR by aprepitant was also seen in primary human keratinocytes. In addition to itch reduction through partial activation of shared EGFR pathways, aprepitant exerts a dose-dependent cytotoxicity to epithelial cells, which may contribute to its antitumor effects.
- Published
- 2019
- Full Text
- View/download PDF
27. The LUCA project - Laser and ultrasound co-analyzer for thyroid nodules: Overview and current status
- Author
-
Davide Contini, K. Krischak, Mireia Mora, S. Konugolu Venkata Sekar, Ramon Gomis, Stanislaw Wojtkiewicz, G. Lo Presti, Paola Taroni, P. Zolda, A. Dalla Mora, Gloria Aranda, Alberto Tosi, Turgut Durduran, Udo M. Weigel, Antonio Pifferi, Lorenzo Cortese, Emilio José García, Bogdan Rosinski, Mauro Buttafava, Mattia Squarcia, Hamid Dehghani, Felicia A. Hanzu, S. de Fraguier, and Marco Renna
- Subjects
Thyroid nodules ,Materials science ,sezele ,business.industry ,Ultrasound ,medicine.disease ,Laser ,Photon counting ,030218 nuclear medicine & medical imaging ,3. Good health ,law.invention ,03 medical and health sciences ,SPAD ,0302 clinical medicine ,Optics ,NIRS ,law ,Fiber laser ,medicine ,Current (fluid) ,Time-resolved spectroscopy ,business ,Thyroid cancer ,030217 neurology & neurosurgery - Abstract
We present the current status of the LUCA-project whose aim is to develop an innovative device combining ultrasound and diffuse optics for an improved screening of the thyroid cancer.
- Published
- 2018
28. Spontaneous Ureterocolic Fistula between Nonfunctioning Kidney Transplant Ureter and Colon in Setting of Diverticulitis
- Author
-
K. Krischak, Madison, R. Ord, Jeffrey, A. Connor, Ashton, and S. Barbas, Andrew
- Abstract
Ureterocolic fistula is a rare condition that most commonly occurs in the setting of diverticular disease. The development of a ureterocolic fistula following kidney transplantation is even rarer, with no prior cases in the literature to our knowledge. We describe the case of a patient with three prior failed kidney transplants who developed a fistula between the sigmoid colon and nonfunctioning renal transplant ureter in the setting of diverticulitis.
- Published
- 2021
- Full Text
- View/download PDF
29. CHAIMELEON Project: Creation of a Pan-European Repository of Health Imaging Data for the Development of AI-Powered Cancer Management Tools.
- Author
-
Bonmatí LM, Miguel A, Suárez A, Aznar M, Beregi JP, Fournier L, Neri E, Laghi A, França M, Sardanelli F, Penzkofer T, Lambin P, Blanquer I, Menzel MI, Seymour K, Figueiras S, Krischak K, Martínez R, Mirsky Y, Yang G, and Alberich-Bayarri Á
- Abstract
The CHAIMELEON project aims to set up a pan-European repository of health imaging data, tools and methodologies, with the ambition to set a standard and provide resources for future AI experimentation for cancer management. The project is a 4 year long, EU-funded project tackling some of the most ambitious research in the fields of biomedical imaging, artificial intelligence and cancer treatment, addressing the four types of cancer that currently have the highest prevalence worldwide: lung, breast, prostate and colorectal. To allow this, clinical partners and external collaborators will populate the repository with multimodality (MR, CT, PET/CT) imaging and related clinical data. Subsequently, AI developers will enable a multimodal analytical data engine facilitating the interpretation, extraction and exploitation of the information stored at the repository. The development and implementation of AI-powered pipelines will enable advancement towards automating data deidentification, curation, annotation, integrity securing and image harmonization. By the end of the project, the usability and performance of the repository as a tool fostering AI experimentation will be technically validated, including a validation subphase by world-class European AI developers, participating in Open Challenges to the AI Community. Upon successful validation of the repository, a set of selected AI tools will undergo early in-silico validation in observational clinical studies coordinated by leading experts in the partner hospitals. Tool performance will be assessed, including external independent validation on hallmark clinical decisions in response to some of the currently most important clinical end points in cancer. The project brings together a consortium of 18 European partners including hospitals, universities, R&D centers and private research companies, constituting an ecosystem of infrastructures, biobanks, AI /in-silico experimentation and cloud computing technologies in oncology., Competing Interests: Authors AS, MA were employed by Matical Innovation SL. MM was employed by GE Healthcare. KS was employed by Medexprim. SF way employed by Bahia Software S.L.U. AA-B way employed by QUIBIM SL. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer KL declared a past co-authorship with several of the authors LM, PL to the handling editor., (Copyright © 2022 Bonmatí, Miguel, Suárez, Aznar, Beregi, Fournier, Neri, Laghi, França, Sardanelli, Penzkofer, Lambin, Blanquer, Menzel, Seymour, Figueiras, Krischak, Martínez, Mirsky, Yang and Alberich-Bayarri.)
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.